Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee. French JA, et al. Among authors: fischer jh. Epilepsia. 2004 May;45(5):410-23. doi: 10.1111/j.0013-9580.2004.06304.x. Epilepsia. 2004. PMID: 15101822 Free article. Review.
Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. French JA, et al. Among authors: fischer jh. Neurology. 2004 Apr 27;62(8):1252-60. doi: 10.1212/01.wnl.0000123693.82339.fc. Neurology. 2004. PMID: 15111659 Review.
Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. French JA, et al. Among authors: fischer jh. Neurology. 2004 Apr 27;62(8):1261-73. doi: 10.1212/01.wnl.0000123695.22623.32. Neurology. 2004. PMID: 15111660 Review.
Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee. French JA, et al. Among authors: fischer jh. Epilepsia. 2004 May;45(5):401-9. doi: 10.1111/j.0013-9580.2004.06204.x. Epilepsia. 2004. PMID: 15101821 Free article. Review.
Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83.
Beydoun A, Fischer J, Labar DR, Harden C, Cantrell D, Uthman BM, Sackellares JC, Abou-Khalil B, Ramsay RE, Hayes A, Greiner M, Garofalo E, Pierce M. Beydoun A, et al. Neurology. 1997 Sep;49(3):746-52. doi: 10.1212/wnl.49.3.746. Neurology. 1997. PMID: 9305335 Clinical Trial.
Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas.
Holdhoff M, Nicholas MK, Peterson RA, Maraka S, Liu LC, Fischer JH, Wefel JS, Fan TM, Vannorsdall T, Russell M, Iacoboni M, Tarasow TM, Hergenrother PJ, Dudek AZ, Danciu OC. Holdhoff M, et al. Among authors: fischer jh. Neurooncol Adv. 2023 Jul 19;5(1):vdad087. doi: 10.1093/noajnl/vdad087. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37554223 Free PMC article.
Global assessment of marine plastic exposure risk for oceanic birds.
Clark BL, Carneiro APB, Pearmain EJ, Rouyer MM, Clay TA, Cowger W, Phillips RA, Manica A, Hazin C, Eriksen M, González-Solís J, Adams J, Albores-Barajas YV, Alfaro-Shigueto J, Alho MS, Araujo DT, Arcos JM, Arnould JPY, Barbosa NJP, Barbraud C, Beard AM, Beck J, Bell EA, Bennet DG, Berlincourt M, Biscoito M, Bjørnstad OK, Bolton M, Booth Jones KA, Borg JJ, Bourgeois K, Bretagnolle V, Bried J, Briskie JV, Brooke ML, Brownlie KC, Bugoni L, Calabrese L, Campioni L, Carey MJ, Carle RD, Carlile N, Carreiro AR, Catry P, Catry T, Cecere JG, Ceia FR, Cherel Y, Choi CY, Cianchetti-Benedetti M, Clarke RH, Cleeland JB, Colodro V, Congdon BC, Danielsen J, De Pascalis F, Deakin Z, Dehnhard N, Dell'Omo G, Delord K, Descamps S, Dilley BJ, Dinis HA, Dubos J, Dunphy BJ, Emmerson LM, Fagundes AI, Fayet AL, Felis JJ, Fischer JH, Freeman AND, Fromant A, Gaibani G, García D, Gjerdrum C, Gomes ISGC, Forero MG, Granadeiro JP, Grecian WJ, Grémillet D, Guilford T, Hallgrimsson GT, Halpin LR, Hansen ES, Hedd A, Helberg M, Helgason HH, Henry LM, Hereward HFR, Hernandez-Montero M, Hindell MA, Hodum PJ, Imperio S, Jaeger A, Jessopp M, Jodice PGR, Jones CG, Jones CW, Jónsson JE, Kane A, Kapelj S, Kim Y, … See abstract for full author list ➔ Clark BL, et al. Among authors: fischer jh. Nat Commun. 2023 Jul 4;14(1):3665. doi: 10.1038/s41467-023-38900-z. Nat Commun. 2023. PMID: 37402727 Free PMC article.
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies.
Danciu OC, Holdhoff M, Peterson RA, Fischer JH, Liu LC, Wang H, Venepalli NK, Chowdhery R, Nicholas MK, Russell MJ, Fan TM, Hergenrother PJ, Tarasow TM, Dudek AZ. Danciu OC, et al. Among authors: fischer jh. Br J Cancer. 2023 Mar;128(5):783-792. doi: 10.1038/s41416-022-02089-7. Epub 2022 Dec 5. Br J Cancer. 2023. PMID: 36470974 Free PMC article. Clinical Trial.
170 results